The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Major Depressive Disorder (MDD) is a complex disease characterized by emotional, physical and cognitive symptoms. We explored the efficacy of vortioxetine versus placebo on outcomes of cognition, functioning and mood symptoms in working patients with depression, using paroxetine as an active reference. METHODS: Gainfully employed patients (18-65 years, N = 152) with MDD were randomized 1:1:1 to 8 weeks' double-blind, parallel treatment either with vortioxetine (10mg/day) or paroxetine (20mg/day), or with placebo. The primary efficacy measure was the Digit Symbol Substitution Test (DSST), analyzed using a mixed model for repeated measurements, and the key secondary efficacy measure was the University of San Diego Performance-based Skills Assessment - Brief (UPSA-B), analyzed using analysis of covariance (last observation carried forward). RESULTS: At week 8, DSST and UPSA-B performance had improved relative to baseline in all treatment groups, with no statistically significant differences between treatment groups. While improvements in mood were comparable for vortioxetine and paroxetine, numerical improvements in cognitive performance (DSST) were larger with vortioxetine. Vortioxetine significantly improved overall cognitive performance and clinician-rated functioning relative to placebo. The majority of adverse events were mild or moderate, with nausea being the most common adverse event for vortioxetine. LIMITATIONS: Small sample sizes implied limited statistical power. CONCLUSION: This explorative study showed no significant differences versus placebo in DSST or UPSA-B performance at week 8. However, secondary results support vortioxetine as an effective and well-tolerated antidepressant, supporting an added benefit for cognition and functioning, which could have particular therapeutic relevance for the working patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
The Epidemiology of Depression Across Cultures
Kessler, R. C., & Bromet, E. J. (2013) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031912-114409 · Cited by 2,657
Cognitive impairment in depression: a systematic review and meta-analysis
Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014) · Psychological Medicine · doi:10.1017/s0033291713002535 · Cited by 2,161
Studies of interference in serial verbal reactions.
Stroop, J. R. (1992) · Journal of Experimental Psychology: General · doi:10.1037/0096-3445.121.1.15 · Cited by 918
Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder
Rosa, A. R., Sánchez-Moreno, J., Martínez-Aran, A., Salamero, M., Torrent, C., Reinares, M., Comes, M., Colom, F., Van Riel, W., Ayuso-Mateos, J., et al. (2007) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-3-5 · Cited by 905
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Neurocognitive deficits and disability in major depressive disorder
Jaeger, J., Berns, S., Uzelac, S., & Davis-Conway, S. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.11.011 · Cited by 484
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445
Self-citation
Cited by
Furukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30217-2 · Cited by 322
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
Vortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75
Baune, B. T., Sampson, E., Louise, J., Hori, H., Schubert, K. O., Clark, S. R., Mills, N. T., & Fourrier, C. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.07.092 · Cited by 62
Self-citationHuang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac054 · Cited by 41
“Two of the trials failed to mention safety issues or side effects (Baune et al., 2018; Smith et al., 2018).”
BackgroundInfluential
Metadata
- Authors
- Baune, B. T., Sluth, L. B., & Olsen, C. K.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 229
- Pages
- 421-428
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2778627188
- Cited by
- 73
- References
- 24
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. https://app.cochat.ai/papers/10.1016/j.jad.2017.12.056
- The paper
- Baune, B. T., Sluth, L. B., & Olsen, C. K. (2018). The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2017.12.056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.